Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Horizon Therapeutics

Explore full profile

Biopharmaceutical company focused on researching, developing, and commercializing innovative medicines that address critical needs for people affected by rare and rheumatic diseases

Dublin, IrelandFounded 2005Biotech & Life Sciences
Valuation $28B Market cap · 2026
Revenue $3.63B Latest reported FY
EBITDA $1.37B Latest reported FY

At a glance

Status
Listed
Founded
2005
Headquarters
Dublin, Ireland
Listing
IPO 2011
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later2 investors entered at this stage

  • Essex Woodlands Health Ventures
  • Scale Venture Partners

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
25 countries with
team presence
🇺🇸 United States78.7%
🇮🇪 Ireland8.6%
🇵🇰 Pakistan1.8%
🇨🇦 Canada1.5%
🇮🇳 India1.3%
Top 5 of 25 shown
Web traffic by country
850 monthly visits
across markets
🇺🇸 United States105.9%
Top 1 markets shown

Patents

Estimated portfolio value
$118M

63 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Horizon Therapeutics was the backer or acquirer, 2010–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

8 deals across Horizon Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Horizon Therapeutics's portfolio, mapped.

        Stage
        Period
        8 of 8 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Horizon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Horizon Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles